HR 6167, the HEALTH Act of 2025, creates a new tax deduction for physicians providing unreimbursed charity care to patients enrolled in Medicaid (Title XIX) or CHIP (Title XXI) programs. The deduction equals the Medicare fee schedule amount for such care, but excludes services like sex reassignment surgeries and hormone treatments for gender transition. Additionally, the bill adds liability protection for physicians providing this charity care, shielding them from civil lawsuits for non-intentional harm during such services, and preempts conflicting state laws. This directly affects physicians who serve low-income patients through public health programs.
SJRES 84 is a joint resolution seeking to block a rule issued by the Centers for Medicare & Medicaid Services (CMS) under the Affordable Care Act. The rule, published in the Federal Register on June 25, 2025, aimed to improve affordability and integrity in health insurance marketplaces. If approved, this resolution would invalidate the rule under a federal disapproval process, preventing its implementation. This directly affects how health insurance plans are structured and priced for consumers using ACA marketplaces.
This bill repeals two provisions from a previous reconciliation act that reduced Medicaid funding flexibility for states and rescinds related funds. It directly affects Medicaid programs and rural hospitals by restoring prior funding structures and adding $10 billion annually from 2031 through 2035 to the Rural Health Transformation Program. Key mechanisms include undoing changes to state Medicaid provider tax authority and state-directed payments, while increasing annual funding for rural hospital support. The bill makes concrete policy changes by reversing specific funding cuts and guaranteeing new, sustained investment for rural healthcare facilities.
HJRES 123 is a congressional disapproval resolution targeting a specific rule by the Centers for Medicare & Medicaid Services (CMS). It seeks to nullify CMS's June 2025 rule titled "Patient Protection and Affordable Care Act; Marketplace Integrity and Affordability," which was published in the Federal Register (90 Fed. Reg. 27074). If passed, the resolution would block this rule from taking effect under procedures outlined in Title 5, U.S. Code. The bill directly affects the CMS regulation governing the Affordable Care Act's health insurance marketplace, not the broader law itself.
This bill requires Medicare to cover "prescription digital therapeutics" (software-based treatments for medical conditions, like apps for diabetes management or mental health) starting January 1, 2026. It mandates Medicare to establish payment rules for manufacturers - considering actual costs and usage - and create specific billing codes for these tools. Manufacturers must annually report pricing, distribution volume, and user data to Medicare, with penalties for noncompliance. The bill directly affects Medicare beneficiaries, digital therapeutic developers, and healthcare providers who prescribe these digital health tools.
This bill creates a streamlined process for out-of-state healthcare providers to enroll in Medicaid or CHIP (Children's Health Insurance Program) in a state. It directly affects children under 21 enrolled in these programs and healthcare providers located in other states who already meet low fraud risk standards. The key provision requires states to adopt a simplified enrollment process using only basic provider information (like name and National Provider Identifier), granting eligible providers a 5-year enrollment period without repeated screening. This reduces administrative barriers for providers serving out-of-state children under 21 who qualify for Medicaid or CHIP coverage.
HR 4796, the Restoring Essential Healthcare Act, repeals a provision that blocked Medicaid payments to certain healthcare providers during a specific period. It directly affects Medicaid beneficiaries who received care from these providers between the enactment of the prior law (Public Law 119-21) and this bill's enactment. The key provision retroactively restores Medicaid payments for services already provided during that blocked period, treating the payment restriction as if it never existed. This change ensures eligible individuals and providers receive reimbursement for covered care delivered during the prohibited timeframe.
This bill clarifies that states can use direct primary care arrangements under Medicaid, where patients pay a fixed monthly fee for primary care services (like check-ups and preventive care) instead of traditional billing. It directly affects Medicaid beneficiaries, primary care providers, and state Medicaid agencies by allowing states to contract with providers for this model through managed care organizations. Key provisions require the Health Secretary to issue implementation guidance within one year and submit a report to Congress within two years analyzing how states use these arrangements and their impact on care quality and costs. The bill does not change existing Medicaid requirements for cost-sharing or the scope of covered services.
This bill requires all U.S. hospitals to publicly list their standard prices for common services within six months of enactment (or six months after opening for new hospitals) and update this list annually. Hospitals must ensure this pricing information is accessible online and cannot hide it from search results. Non-compliant hospitals face daily fines - ranging from $600 per day for small hospitals to $11,000 per day for large facilities - based on bed size, with the government publishing a public list of violators every six months. The law aims to make healthcare pricing transparent for patients and enforceable through specific penalties.
HR 5094, the "Protect Patients from Costly Care Act," repeals two specific provisions from a prior reconciliation law (Public Law 119-21) that would have increased patient costs. It restores Medicaid cost sharing rules to their pre-2023 state, directly affecting Medicaid beneficiaries by preventing higher out-of-pocket costs. It also reverses changes to orphan drug exclusions under the Drug Price Negotiation Program, bringing those medications back under federal price negotiation rules for manufacturers. The bill does not create new policies but undoes specific cost-increasing changes to existing programs.
